Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IDEC-C2B8 chimeric antibody targeted to the CD20 receptor on B cells data

In a Phase I trial in 15 patients, six of nine patients receiving the three highest of five doses tested had reductions in tumor size. Two of the patients' tumors

Read the full 300 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE